Individuals Discontinuing Slimming Jabs Regain Pounds at a Quadrupled Rate Than Those on Conventional Diets

New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt traditional lifestyle regimens.

Research printed in a leading health publication points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.

"Users buying these treatments need to be aware of the danger of rapid rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.

That rate of regain means a reversion to original mass in about one and a half years.

Weighing Therapies

The research, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.

The team note that individuals who lose weight through diet and exercise generally experience a slower creep back—approximately 0.1 kg a month—after stopping.

Explaining the Quick Regain

Nutrition scientists propose the mechanism of the drugs is key to understanding the accelerated regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of the hormone concentrations far above than normal might result in the body to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making excessive eating far more likely."

A Lifelong Disease?

Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.

Many experts argue that, given the likelihood of weight regain, the treatment should be considered long-term.

This view is supported by drug manufacturers, who say that the results "underscore the persistent character of obesity," comparing it to managing diseases like diabetes.

User Accounts

People who have stopped the medication describe a powerful return of appetite.

"It was like a trigger that goes on and you're instantly starving," described an individual.

This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit modifications during treatment.

Significant Interest

Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.

• Adoption is higher among women than males.
• The 40s and 50s age group shows the greatest usage rates.
• Many access the drugs through private prescriptions rather than the NHS.

Finally, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated behavioural changes.